Printer Friendly

Toyama Chemical Launches Phase I Clinical Trials of Anti-rheumatic Agent T-5224.

Tokyo, Japan, June 23, 2006 - (JCN) - Toyama Chemical has commenced phase I clinical trials of T-5224, its proprietary drug candidate for the treatment of rheumatoid arthritis (RA).

A low-molecular compound that inhibits an activator protein 1 (AP-1), T-5224 alleviates inflammation and joint destruction so it is expected to be used as a basic remedy for RA.

The development of T-5224 has been sponsored by the Japan Science and Technology Agency.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jun 23, 2006
Previous Article:Mebix, So-net M3 to Form Business Alliance.
Next Article:Riken Discovers New Mechanism for Controlling Allergic Reactions.

Related Articles
Toyama Chemical Begins US Phase I Clinical Trial for Neurotrophic Agent T-817MA for Alzheimer's Disease Treatment.
Sosei UK Subsidiary Starts Phase IIb Clinical Trial of AD 452, Investigational Drug for Treating Rheumatoid Arthritis.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on...
Otsuka Pharmaceutical Releases New Quinolone Antibiotic Eyedrops.
Tanabe Seiyaku Launches New Anti-rheumatic.
Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |